Next Generation Point of Care Drug Detection Product Submitted
to FDA for 510 k Clearance

HERNDON, Va.(BUSINESS WIRE)Oct. 3, 1997The Fingerprint Drug Screening
Device(TM), the only drug screening product available that links drug
testing results with an identifiable fingerprint, has just been submitted
to the FDA for 510(k) clearance.

Developed and to be marketed by Point of Care Technologies Inc. (Point of
Care), this rapid noninstrument assay was created to detect the presence
of illicit drugs in urine.

"We expect to receive FDA clearance quickly since the Fingerprint Drug
Screening Device is an improved version of our first generation drug
screening product and is based on technology which has previously been FDA
cleared," stated Michael R. Pratt, president and CEO.

"As soon as we receive clearance, we will immediately begin shipping to
fill stocking orders placed by our network of distributors."

Developed after years of research, the Fingerprint Drug Screening Device
tests for amphetamines, cocaine, opiates, PCP and THC (marijuana) in
minutes, meets all NIDA (National Institute on Drug Abuse) cutoff
standards and can be easily administered.

The product's ability to generate an "identifiable" fingerprint of the
person being tested as an integral part of the test has special
significance in the law enforcement and judicial process.

This unique feature of the Fingerprint Drug Screening Device eliminates
doubt in establishing chain of custody. There is also a significant
interest in the product from the educational and international customs
sectors.

Point of Care, based in Herndon, is an emerging leader in the development
and distribution of efficient and reliable screening and diagnostic
products for use in the home and at the point of care. Point of Care is
traded on the NASDAQ bulletin board under the symbol PCIT.

CONTACT: Point of Care Technologies Inc.

Brian Harmison, 703/7130589
or
Arnold Public Relations
Robert Ranson, 703/9057173